scholarly journals The Aspect of Voice Characteristics Change after Botulinum Toxin-A Injection in Patients with Adductor Spasmodic Dysphonia according to Vocal Tremor

2012 ◽  
Vol 4 (4) ◽  
pp. 95-107 ◽  
Author(s):  
Hyeju Ko ◽  
Hong-Shik Choi ◽  
Sung-Eun Lim ◽  
Yaelin Choi
2019 ◽  
Vol 130 (3) ◽  
pp. 741-746 ◽  
Author(s):  
Juliëtta H. C. Schuering ◽  
Bas J. Heijnen ◽  
Elisabeth V. Sjögren ◽  
Antonius P. M. Langeveld

2017 ◽  
Vol 31 (3) ◽  
pp. 363-365 ◽  
Author(s):  
Joseph P. Bradley ◽  
Emily M. Barrow ◽  
Edie R. Hapner ◽  
Adam M. Klein ◽  
Michael M. Johns

2007 ◽  
Vol 122 (1) ◽  
pp. 52-56 ◽  
Author(s):  
P Casserly ◽  
C Timon

AbstractSpasmodic dysphonia is a disabling voice condition caused by a chronic neurological disorder of central motor processing. Present therapy is directed at relief of symptoms rather than cure. Botulinum toxin type A injection into the thyroarytenoid muscle has become the pre-eminent approach for treatment of adductor spasmodic dysphonia. Botulinum toxin A injections can be performed in an out-patient setting under electromyographic guidance. We present our experience with 153 injections in 14 patients with adductor spasmodic dysphonia over a 10-year period. We demonstrate that the electromyography signal is a reliable prognostic indicator in terms of efficacy, and that patients' subjective opinion is a valid indicator of treatment success and future treatment strategy.


2005 ◽  
Vol 133 (6) ◽  
pp. 836-838 ◽  
Author(s):  
Andrew Blitzer

OBJECTIVE: The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles. METHODS: Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 Uof BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response. RESULTS: The conversion factor was found to be 52.3 U:1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [ P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [ P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth. CONCLUSION: This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia. EBM RATING: B-2


2021 ◽  
Author(s):  
Yin Yiu ◽  
Teresa Procter

The larynx is critical to performing complex tasks of airway protection, phonation, respiration, and deglutition. Various focal and systemic neurologic disorders impact the larynx, causing deficits that lead to dysfunction in voice, speech, breathing, and swallowing function. The most common hyperfunctional neurolaryngeal disorders include spasmodic dysphonia (laryngeal dystonia), essential vocal tremor, and muscle tension dysphonia. Some hypofunctional neurolaryngeal disorders include parkinsonian disorders, neuromuscular junction diseases, and myopathies. A multidisciplinary approach involving evaluation by neurologists, voice-trained otolaryngologists and speech-language pathologists is often key to diagnosis and treatment of these challenging and sometimes lifelong disorders. Botulinum toxin injection into the laryngeal musculature is currently the gold-standard treatment for both spasmodic dysphonia and vocal tremor. However, much research is being conducted to advance less invasive and more definitive medical and surgical treatment interventions. This review contains 3 figures, 11 videos, 6 tables and 29 references Keywords: laryngeal neurophysiology, laryngeal dystonia, adductor spasmodic dysphonia, abductor spasmodic dysphonia, essential vocal tremor, hyperfunctional voice disorders, hypofunctional voice disorders, botulinum toxin injection


Sign in / Sign up

Export Citation Format

Share Document